Novo Nordisk has licensed Hengrui’s oral GLP-1/GIP candidate HRS-1596 in a deal worth up to $2.6bn, with $300m upfront plus royalties.
The Danish obesity leader gets global rights to the drug outside mainland China, Hong Kong, Macao and Taiwan. Hengrui keeps those markets.
The deal at a glance
- Upfront: $300m
- Total value: Up to $2.6bn, including development, regulatory and commercial milestones
- Royalties: Paid to Hengrui on net sales in Novo’s territories
- Molecule: HRS-1596, a dual GLP-1 and GIP receptor agonist
- Stage: Ready to enter phase 1
- Dosing: Potentially once-weekly, taken orally
Why a pill matters
Today’s leading obesity drugs are mostly injectables. An oral treatment taken once a week could be easier for patients and simpler to supply at scale. Dual GLP-1/GIP agonists are seen as one of the most promising approaches in the category.
Why it matters
- The obesity race is moving to oral drugs. Major players are competing to offer pills alongside injections.
- China as an innovation source. Like other large drugmakers, Novo is licensing early-stage assets from Chinese biotechs.
- Early-stage risk. HRS-1596 has yet to enter human trials, so success is far from certain.
What it means for the supply chain
Oral medicines generally avoid the capacity bottlenecks of injectables, such as pen devices and sterile fill-finish. If oral obesity drugs succeed, demand could shift towards solid-dose manufacturing, active ingredient supply and standard pharmacy distribution. That would ease pressure on the injectable supply chain that has struggled to keep up with demand.
The bottom line
Novo’s $300m upfront payment buys an early option on a once-weekly obesity pill. It is a long-term bet, but it shows where the market expects obesity treatment to head.
Frequently Asked Questions
What is HRS-1596? A dual GLP-1 and GIP receptor agonist from Hengrui, which could potentially be taken orally once a week.
How much is Novo paying? $300m upfront, with the total deal worth up to $2.6bn, plus royalties.
Which markets does Novo get? Global rights excluding mainland China, Hong Kong, Macao and Taiwan.
What stage is the drug at? It is ready to begin phase 1 clinical trials.
Sources
| Source | Used for |
|---|---|
| Indian Pharma Post | Deal terms, molecule and territories |
| Novo Nordisk company announcement | Licensing agreement |
| Contract Pharma | Deal coverage |
Additional Resources
| Resource | What you’ll find |
|---|---|
| Novo Nordisk investor relations | Obesity portfolio and pipeline updates |
| Jiangsu Hengrui Pharmaceuticals investor relations | Company announcements |
| ClinicalTrials.gov | Registered obesity and diabetes trials |
| World Health Organization (WHO) | Global obesity data |
Data note: Planned trial timelines for HRS-1596 were not confirmed in available reporting.